Skinvisible, Inc. (SKVI)
OTCMKTS · Delayed Price · Currency is USD
0.2000
-0.0299 (-13.01%)
Sep 12, 2025, 3:48 PM EDT
Skinvisible Revenue
Skinvisible had revenue of $5.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $20.00K. In the year 2024, Skinvisible had annual revenue of $20.00K.
Revenue
20.00K
Revenue Growth
n/a
P/S Ratio
54.04
Revenue / Employee
10.00K
Employees
2
Market Cap
1.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | - | - |
Dec 31, 2023 | 20.00K | -259.30K | -92.84% |
Dec 31, 2022 | 279.30K | -384.13K | -57.90% |
Dec 31, 2021 | 663.43K | 387.87K | 140.76% |
Dec 31, 2020 | 275.56K | 232.39K | 538.36% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cordyceps Sunshine Biotech Holdings | 1.25M |
Microalliance Group | 22.88M |
Cuisine Solutions | 80.48M |
Armanino Foods of Distinction | 73.15M |
South Dakota Soybean Processors, LLC | 485.00M |
ESG Inc. | 11.87M |
Crimson Wine Group | 71.27M |
Pyxus International | 2.36B |
Skinvisible News
- 8 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 8 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 1 year ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 1 year ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 1 year ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 1 year ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire